IBI346 / Innovent Biologics - LARVOL DELTA

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: The First Affiliated Hospital of Soochow University | Recruiting ➔ Completed | N=42 ➔ 6 | Trial completion date: Feb 2024 ➔ May 2023 | Trial primary completion date: Feb 2024 ➔ Dec 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

SAFETY AND EFFICACY OF IBI346, A FIRST-IN-CLASS BCMA-TARGETING MODULAR CAR-T CELL THERAPY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM TWO PHASE I STUDIES (EHA 2023) - P1 | "BCMA-targeting modular P329G-CAR-T cell therapy IBI346 was well tolerated and showed preliminary clinical activity in heavily pretreated pts with RRMM. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G antibody and CAR-T cells requires further exploration. Correspondence to Dr."

CAR T-Cell Therapy • Clinical • IO biomarker • P1 data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Chunrui Li | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology